Related Experiment Videos

Apoptosis in neuroendocrine tumours

D G Wang1

  • 1Center for Molecular Medicine, School of Medicine, University of Connecticut Health Center, Farmington CT 06030-3101, USA. dwang@nso2.uchc.edu

Clinical Endocrinology
|September 1, 1999
PubMed

Insights

Neuroendocrine tumors (NETs) resist apoptosis, promoting cancer growth and chemoresistance. Targeting programmed cell death pathways offers potential for new NET treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Acquired resistance to apoptosis contributes to neuroendocrine tumor (NET) clonal expansion and persistence.
  • Deregulation of programmed cell death is critical in NET multistep tumorigenesis.
  • Frequent Bcl-2 oncoprotein expression in NETs may play a role in their pathogenesis.

Purpose of the Study:

  • To investigate the role of apoptosis resistance in neuroendocrine tumor development.
  • To explore the potential link between Bcl-2, c-Myc, and NET multistep tumorigenesis.
  • To understand how oncogenes influence cell death rates in cancer biology.

Main Methods:

  • Analysis of apoptosis resistance mechanisms in NETs.
  • Investigation of Bcl-2 and c-Myc genetic complementation in NETs.
  • Correlation of apoptosis resistance with chemoresistance in NETs.

Main Results:

  • Apoptosis resistance in NETs facilitates clonal expansion and tumor growth.
  • Simultaneous deregulation of Bcl-2 and c-Myc may be implicated in human NET tumorigenesis.
  • Apoptosis resistance typically correlates with chemoresistance in NETs.

Conclusions:

  • Understanding apoptosis deregulation in NETs is crucial for pathogenesis.
  • Targeting programmed cell death pathways may lead to more effective NET treatments.
  • Inducing programmed cell death could be an integral component of curative NET therapies.

Related Concept Videos